newsfilter
← Latest News
GlobeNewswire·

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

ASND
  • Eyconis, Inc. has initiated the OVERTURE Phase 1b/2a clinical trial, marking its transition to a clinical-stage biotechnology company.
  • The first patients with treatment-naïve wet age-related macular degeneration (AMD) have been dosed in this first-in-human study.
  • The investigational therapy EYC-0305 utilizes Ascendis Pharma's TransCon technology platform to deliver sustained anti-VEGF activity.
  • The trial design targets six-month or longer dosing intervals via standard intravitreal injection, eliminating the need for traditional monthly loading doses.
  • OVERTURE is an open-label, multiple ascending dose study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, disease activity, vision, and potential durability beyond six months.
  • Wet AMD remains a leading cause of severe vision loss in older adults, driving the need for therapies that extend dosing intervals while maintaining disease control.
  • EYC-0305 is currently an unapproved investigational antibody fragment being developed for wet AMD with potential applicability to other retinal diseases such as diabetic macular edema, diabetic retinopathy, and retinal vein occlusion.
  • The study identifier for OVERTURE is NCT07587515 on ClinicalTrials.gov.
  • Eyconis holds an exclusive worldwide license for ophthalmology from Ascendis Pharma to utilize the TransCon technology platform.